HiFiBiO Therapeutics to Present Updated Phase 1 Clinical Data of Two Immuno-Oncology Programs at the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) 

On September 25, 2025 HiFiBiO Therapeutics, a clinical stage immune modulation biotechnology company, reported its participation in the 2025 Annual Meeting of the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper), taking place October 17-21 in Berlin, Germany (Press release, HiFiBiO Therapeutics, SEP 25, 2025, View Source [SID1234656237]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The company will present exciting Phase 1 clinical data on two immuno-oncology programs: the first-in-class anti-TNFR2 agonist emunkitug, and an anti-BTLA antagonist with best-in-class potential, HFB200603. The posters will report updated safety and efficacy results along with potential predictive biomarkers of clinical benefit.

HiFiBiO’s novel immunotherapies powered by AI/ML and its single-cell translational platform demonstrate the company’s deep commitment to the development of impactful therapies to address unmet medical needs.

Details of the poster presentation are as follows:

Presentation # 994P

Title: Potential Predictive Biomarkers of Clinical Benefit from Emunkitug (HFB200301) in Combination with Tislelizumab: Integrated Analysis of Tumor, Peripheral Blood, and Patient Treatment History.

Session Date: Sunday, October 19, 2025

Session Time: 12:00 – 12:45 CEST

Speaker: Desamparados Roda, MD, PhD, Hospital Clínico de Valencia

Presentation # 949P

Title: Evaluation of HVEM and PD-L1 Expression Profile in Tumors as Potential Predictive Biomarkers for HFB200603, a BTLA antagonist, as Monotherapy and in Combination with Tislelizumab.

Session Date: Sunday, October 19, 2025

Session Time: 12:00 – 12:45 CEST

Speaker: María de Miguel, MD, PhD, Hospital Universitario HM Sanchinarro